Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/2/2020
SIETES contiene 92916 citas

 
 
 1 a 20 de 26 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, Quaratino D. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015;136:685-91. [Ref.ID 99527]
2. Cita con resumen
Anónimo. Céfépime: effets indésirables neurologiques graves. Prescrire 2014;34:511. [Ref.ID 98073]
3. Cita con resumen
Ramírez E, Rossignoli T, Campos AJ, Muñoz R, Zegarra C, Tong H, Medrano N, Borobia AM, Carcas AJ, Frías J. Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals . Eur J Clin Pharmacol 2013;69:97-110. [Ref.ID 94842]
4. Cita con resumen
Anónimo. Cefepime: risk of seizure. United States of America. WHO Drug Information 2012;26:265-6. [Ref.ID 93687]
5. Cita con resumen
Aldea A, García Sánchez-Colomer M, Fernández Quintana E, García Sáiz M. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol 2012;68:1329-38. [Ref.ID 93650]
7. Cita con resumen
Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]
8. Cita con resumen
Anónimo. FDA explores cefepime and increased mortality link. Scrip 2007;3314:22. [Ref.ID 81591]
9. Cita con resumen
Anónimo. Cefepime. Reports of death being investigated. USA. WHO Pharmaceuticals Newsletter 2007;6:4. [Ref.ID 78280]
10.
Sánchez-Bailén MJ, Navarro Ciruelos N, Rovira García-Marrón R, Anglès Coll R. Encefalopatía asociada a la administración de cefepime en una paciente con shock séptico e insuficiencia renal. Rev Clin Esp 2004;204:501-2. [Ref.ID 71567]
11. Cita con resumen
Abanades S, Nolla J, Rodríguez-Campello A, Pedro C, Valls A, Farré M. Reversible coma secondary to cefepime neurotoxicity. Ann Pharmacother 2004;38:606-8. [Ref.ID 69656]
12. Cita con resumen
File Jr TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001. [Ref.ID 68472]
13.
Anónimo. Cefepime, ceftazidime and neurotoxicity. WHO Drug Information 2003;17:93-4. [Ref.ID 66841]
14. Cita con resumen
Sáez-Llorens X, McCracken Jr GH. Bacterial meningitis in children. Lancet 2003;361:2139-48. [Ref.ID 66125]
16.
Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000;34:989-95. [Ref.ID 52730]
17.
18.
Anónimo. The choice of antibacterial drugs. Med Lett Drugs Ther 1999;41:95-104. [Ref.ID 47722]
19.
Chetaille E, Hary L, De Cagny B, Gras-Champel V, Decocq G, Andréjak M. Crises convulsives associées à un surdosage en céfépime. Therapie 1998;53:167-8. [Ref.ID 38653]
20.
Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother 1996;30:1414-24. [Ref.ID 30408]
Seleccionar todas
 
 1 a 20 de 26 siguiente >>